Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for IBD patients: can a better antibiotic stop c. diff for good?

NCT ID NCT06794944

Not yet recruiting Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two antibiotics, fidaxomicin and vancomycin, to see which one is better at clearing C. difficile bacteria from the gut in people with inflammatory bowel disease (IBD). About 60 adults with IBD will take one of the two antibiotics for 10 days and be followed for 26 weeks. The goal is to find a treatment that reduces C. diff infections and improves IBD symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Clostridium difficile colitis Clostridium infectious disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLOSTRIDIOIDES DIFFICILE INFECTION INFLAMMATORY BOWEL DISEASE (IBD)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••